GlobalData on MSN9 个月
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depression
The transcranial magnetic stimulation (TMS) device is cleared for use as an adjunct treatment in patients aged 15-21 years ...
来自MSN9 个月
FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
This approval marks NeuroStar as the first and only transcranial magnetic stimulation (TMS) therapy cleared by the FDA for use in this younger demographic, expanding its indications to a fourth ...